SANOFI-ADR (SNY) Stock Price, Quote, News and Summary
NASDAQ:SNY - Nasdaq - US80105N1054 - ADR
SNY Quote and Key Statistics
SANOFI-ADR
NASDAQ:SNY (1/17/2025, 9:32:11 PM)
Premarket: 51.21 +0.47 (+0.93%)50.74
0 (0%)
SNY Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 11.06% | ||
| ROA | 6.07% | ||
| ROE | 10.83% | ||
| Debt/Equity | 0.2 |
SNY Performance and Technical Analysis
SNY Ownership and Analysts
SNY Latest News and Analysis
Why Verona Pharma, A Triple-Digit Gainer In 2024, Surged Another 22% This Week
The company is working to launch its COPD treatment more broadly. The drug is a non-steroidal nebulizer.
Sanofi's Blood Cancer Drug's New Subcutaneous Formulation Hits Primary Goal In Late-Stage In Multiple Myeloma
Sanofi's phase 3 study shows Sarclisa SC matches IV formulation in efficacy for relapsed myeloma. Regulatory submissions are planned for 2025.
Why Cytokinetics Stock Was a Nearly 5% Winner Today
Teva Catapults 20%, Nearing A Five-Year High, After Scoring A Win With Sanofi-Tied Drug
Teva and Sanofi are partnered on a drug to treat inflammatory bowel disease. The drug showed "best-in-class potential" in midstage testing.
Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?
On Tuesday, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Sanofi SA’s (NASDAQ:SNY) Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn’s disease (CD). RELIEVE UCCD investigated duvakitug (TEV’574/SAR447189), a human IgG1-λ2 monoclonal antibody targeting TL1A, for moderate-to-severe inflammatory bowel disease (IBD). In the RELIEVE UCCD study, 36.2% (low-dose) and 47.8% (high-dose) of patients with ulcerative colitis treated with duvakitug
About SNY
Company Profile
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 87,994 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
Company Info
SANOFI-ADR
46 Avenue de la Grande Armee
Paris ILE-DE-FRANCE 75008 FR
CEO: Paul Hudson
Employees: 86088
Company Website: https://www.sanofi.com/
Investor Relations: https://www.sanofi.com/en/investors
Phone: 33153774000
SNY Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 71.36 | 688.94B | ||
| JNJ | JOHNSON & JOHNSON | 14.36 | 353.99B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 26.77 | 349.49B | ||
| MRK | MERCK & CO. INC. | 16.46 | 247.70B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 17.48 | 206.53B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.07 | 194.99B | ||
| PFE | PFIZER INC | 10.19 | 149.04B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.11 | 114.17B | ||
| ZTS | ZOETIS INC | 28.8 | 74.84B | ||
| GSK | GSK PLC-SPON ADR | 8.21 | 68.21B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 21.53 | 40.96B | ||
| TEVA | TEVA PHARMACEUTICAL-SP ADR | 7.88 | 24.83B |